Cara Therapeutics (CARA) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CARA vs. ZURA, ATOS, SNTI, OPTN, HLVX, EXOZ, OCX, CRBP, BDTX, and TCRXShould you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include Zura Bio (ZURA), Atossa Therapeutics (ATOS), Senti Biosciences (SNTI), OptiNose (OPTN), HilleVax (HLVX), Exozymes (EXOZ), OncoCyte (OCX), Corbus Pharmaceuticals (CRBP), Black Diamond Therapeutics (BDTX), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Cara Therapeutics vs. Zura Bio Atossa Therapeutics Senti Biosciences OptiNose HilleVax Exozymes OncoCyte Corbus Pharmaceuticals Black Diamond Therapeutics TScan Therapeutics Cara Therapeutics (NASDAQ:CARA) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation. Do analysts rate CARA or ZURA? Cara Therapeutics presently has a consensus target price of $83.52, suggesting a potential upside of 0.00%. Zura Bio has a consensus target price of $14.67, suggesting a potential upside of 864.91%. Given Zura Bio's stronger consensus rating and higher possible upside, analysts plainly believe Zura Bio is more favorable than Cara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cara Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor CARA or ZURA? In the previous week, Zura Bio had 4 more articles in the media than Cara Therapeutics. MarketBeat recorded 5 mentions for Zura Bio and 1 mentions for Cara Therapeutics. Cara Therapeutics' average media sentiment score of 1.89 beat Zura Bio's score of 0.97 indicating that Cara Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cara Therapeutics Very Positive Zura Bio Positive Do insiders & institutionals believe in CARA or ZURA? 44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by insiders. Comparatively, 22.1% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in CARA or ZURA? Cara Therapeutics received 644 more outperform votes than Zura Bio when rated by MarketBeat users. However, 79.31% of users gave Zura Bio an outperform vote while only 72.03% of users gave Cara Therapeutics an outperform vote. CompanyUnderperformOutperformCara TherapeuticsOutperform Votes66772.03% Underperform Votes25927.97% Zura BioOutperform Votes2379.31% Underperform Votes620.69% Which has stronger valuation & earnings, CARA or ZURA? Zura Bio has lower revenue, but higher earnings than Cara Therapeutics. Zura Bio is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCara Therapeutics$7.14M0.00-$118.51M-$21.01N/AZura BioN/AN/A-$69.24M-$0.53-2.87 Which has more risk and volatility, CARA or ZURA? Cara Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Is CARA or ZURA more profitable? Zura Bio has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Zura Bio's return on equity of -37.36% beat Cara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cara Therapeutics-1,099.76% -367.97% -107.43% Zura Bio N/A -37.36%-29.81% SummaryZura Bio beats Cara Therapeutics on 13 of the 18 factors compared between the two stocks. Get Cara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CARA vs. The Competition Export to ExcelMetricCara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.33M$6.79B$5.53B$7.99BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-0.257.4422.6518.64Price / SalesN/A244.75401.98103.80Price / CashN/A65.8538.1834.62Price / BookN/A6.536.754.30Net Income-$118.51M$143.43M$3.22B$248.44M Cara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CARACara Therapeutics3.8777 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading VolumeZURAZura Bio3.0985 of 5 stars$1.41+2.9%$14.67+940.2%-63.9%$96.41MN/A-2.663Upcoming EarningsShort Interest ↓News CoverageATOSAtossa Therapeutics1.9466 of 5 stars$0.74-1.8%$7.13+859.2%-40.5%$95.95MN/A-3.388Gap UpSNTISenti Biosciences2.8692 of 5 stars$3.64-27.2%$10.00+174.7%-7.8%$94.66M$2.56M-0.234Upcoming EarningsNews CoverageHigh Trading VolumeOPTNOptiNose3.2589 of 5 stars$9.34+0.6%$9.00-3.6%-24.3%$94.59M$78.23M-2.22190Short Interest ↓News CoveragePositive NewsHLVXHilleVax2.779 of 5 stars$1.88+1.6%$3.00+59.6%-85.3%$94.27MN/A-0.6120Upcoming EarningsNews CoveragePositive NewsEXOZExozymesN/A$11.21+4.5%N/AN/A$93.81MN/A0.0029OCXOncoCyte2.1766 of 5 stars$3.22-6.4%$4.42+37.2%+23.7%$92.09M$1.88M-0.73120News CoverageCRBPCorbus Pharmaceuticals4.0315 of 5 stars$7.50-7.2%$59.13+688.3%-79.8%$91.74MN/A-1.6040Upcoming EarningsBDTXBlack Diamond Therapeutics3.527 of 5 stars$1.60+0.6%$14.60+812.5%-69.5%$90.68MN/A-1.2090Upcoming EarningsNews CoveragePositive NewsTCRXTScan Therapeutics3.7651 of 5 stars$1.60flat$9.33+483.3%-79.2%$90.55M$2.82M-1.51100News CoveragePositive News Related Companies and Tools Related Companies Zura Bio Competitors Atossa Therapeutics Competitors Senti Biosciences Competitors OptiNose Competitors HilleVax Competitors Exozymes Competitors OncoCyte Competitors Corbus Pharmaceuticals Competitors Black Diamond Therapeutics Competitors TScan Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CARA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CARA Stock Free CARA Stock Alerts